XASX
CC5
Market cap19mUSD
Dec 23, Last price
0.02AUD
Name
LBT Innovations Ltd
Chart & Performance
P/E
—
P/S
23.80
EPS
—
Div Yield, %
—
Shrs. gr., 5y
26.51%
Rev. gr., 5y
33.25%
Revenues
1m
-41.09%
Net income
-4m
L-83.40%
CFO
-4m
L+162.73%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia, Switzerland, the United States, the United Kingdom, and Germany. The company offers MicroStreak, an automated culture-plate streaking and inoculation system; and Automated Plate Assessment System, a platform technology that automates culture-plate screening and interpretation. It also develops Automated Gram Strain Assessment for the automated interpretation of gram stain image analysis; WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds; Automated Plate Assessment System Pharma, a technology that uses cutting-edge artificial intelligent image analysis algorithms to automatically detect microbial growth for environmental monitoring applications; and devices that can detect biofilms in the presence of mammalian tissue. The company was incorporated in 2004 and is headquartered in Adelaide, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||